You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

254 Results
Regimen
Intent: Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Feb 2022
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • triptorelin
Jun 2017
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Palliative
Nov 2017
Regimen
Cancer Type:
Endocrine, 
Thyroid
Intent: Palliative
Funding:
Exceptional Access Program
    vanDETanib - Monotherapy for symptomatic and/or progressive medullary thyroid cancer (MTC), with specific criteria
Nov 2023
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
    vemURAFenib - Monotherapy in patients with BRAF V600 mutation-positive unresectable stage Ill or stage IV melanoma, with specific criteria
Aug 2023
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Curative
Mar 2021
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
  • trametinib - As monotherapy in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, according to specific criteria
Jun 2021
Regimen
Cancer Type:
Skin, 
Basal Cell
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    vismodegib - Treatment for metastatic basal cell carcinoma (BCC) or with locally advanced BCC (including patients with basal cell nevus syndrome, i.e. Gorlin syndrome), according to specific criteria
Aug 2023
Regimen
Cancer Type:
Gynecologic, 
Endometrial, 
Ovary
Intent: Palliative
Funding:
ODB - General Benefit
    tamoxifen
May 2022
Regimen
Cancer Type:
Central Nervous System
Intent: Palliative
Aug 2017
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Oct 2017
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Aug 2021

Pages